Loading...
•
Dec 31, 2019
Natera Q4 2019 Earnings Report
Reported strong volume growth, consistent average selling price expansion, and reduced cost of goods sold per unit in its reproductive health business.
Key Takeaways
Natera reported a 24% increase in total revenues for Q4 2019, driven by sales of Panorama and Horizon tests. The company processed 209,400 tests, with 198,300 accessioned in its laboratory, and recognized revenue on 200,800 tests reported, including 189,700 tests accessioned in its laboratory.
Total revenues increased by 24% compared to Q4 2018.
Processed 209,400 tests in Q4 2019, a 20% increase year-over-year.
Gross profit for Q4 2019 was $38.8 million, representing a 47% gross margin.
Net loss for Q4 2019 was $35.2 million, or ($0.46) per diluted share.
Forward Guidance
Natera anticipates 2020 total revenue of $335 million to $350 million; 2020 cost of revenues to be approximately 51% to 57% of revenues; selling, general and administrative costs to be approximately $240 million to $260 million; research and development costs to be $80 million to $90 million, and net cash burn to be $125 million to $150 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...